| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/23/2008 | CN100363006C Drug addiction-stopping formulation and preparation thereof |
| 01/23/2008 | CN100363005C Composite preparation for treatment of dementia |
| 01/23/2008 | CN100363004C Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 01/23/2008 | CN100363003C Sustained releasing tablet of buspirone hydrochloride |
| 01/23/2008 | CN100363002C Application of tetrandrine and Fangchinoline in preparation of medicine for improving sleep and health products |
| 01/23/2008 | CN100363001C Moxifloxacin capsule and its preparation method |
| 01/23/2008 | CN100363000C Chinese and western medicines composition contg. Avandia and its prepn. method |
| 01/23/2008 | CN100362999C Antimicrobial medicinal composition and its production process |
| 01/23/2008 | CN100362998C Medicine composition for treating diabetes |
| 01/23/2008 | CN100362997C Enteric coated table of duloxetine, and preparation method |
| 01/23/2008 | CN100362996C Duloxetine enteric coated tiny pill capsule, and preparation method |
| 01/23/2008 | CN100362995C CYP2A enzymes and their use in therapeutic and diagnostic method |
| 01/23/2008 | CN100362994C Preparation for treating allergic rhinitis and asthma |
| 01/23/2008 | CN100362993C Tanshinone emulsion and its making method |
| 01/23/2008 | CN100362992C Nutritional composition for oral use |
| 01/23/2008 | CN100362991C Medicine composition for ophthalmology department |
| 01/23/2008 | CN100362990C Fibrauretine-amino acid fluid for transfusion and its production process |
| 01/23/2008 | CN100362989C Ophthalmic composition containing N-acetyl-cysteine for treatment of dry-eye syndrome |
| 01/23/2008 | CN100362988C Chinese and western medicine composition contg. metformin |
| 01/23/2008 | CN100362987C Particulate product comprising pantethine |
| 01/23/2008 | CN100362986C Dry powder inhalant composition |
| 01/23/2008 | CN100362984C Prepn. method of matrine magnetic micro-ball |
| 01/23/2008 | CN100362931C Method for preparing liver-benefiting, face-beautifying soybean milk powder with micron pine pollen, pearl powder for women |
| 01/22/2008 | USRE40033 Process for preparing 2-methyl-thieno-benzodiazepine |
| 01/22/2008 | US7321065 E.g., N-methyl-O-benzyl-tyramine, 3,5,3',5'-tetraiodothyroethanolamine; antagonist of a G protein coupled receptor and a trace amine receptor; antidepressants; nervous system disorders; antidiabetic agents; antiarrhymia disorders; glandular disorders of the thyroid; congestive heart failure; analgesics |
| 01/22/2008 | US7321059 2,3-diethoxylated propionic acid derivatives, e.g., 20-(7,10,13,16-tetraoxaheptadec-1-yloxy)-2,5,8,11,18-pentaoxahenicosan-21-oic acid; for use in inhalation therapy with propellants for treating respiratory system disorders |
| 01/22/2008 | US7321050 and stilbene oxides; 3,5-dihydroxy-4-isopropylstilbene for example; treating various immune, inflammatory, and autoimmune diseases |
| 01/22/2008 | US7321045 Vitronectin receptor antagonist pharmaceuticals |
| 01/22/2008 | US7321040 MAP (mitogen-activated protein) kinase inhibitors; osteoarthritis, rheumatoid arthritis, anticarcinogenic or antiischemic agents; reperfusion injuries, strokes or heart attack; autoimmune, skin, cardiovascular, brain, bone, neurodegenerative, respiratory system and nervous system disorders |
| 01/22/2008 | US7321033 Having immunomodulatory activity; for therapy and prophylaxis of infections caused by adenovirus, cytomegalovirus, hepatitis A virus (HAV), hepatitis B virus (HBV), flaviviruses including Yellow Fever virus, herpes virus |
| 01/22/2008 | US7321027 Mercaptan containing diagnostic agents for imaging malignant melanoma and distant metastases and rhenium (186Re, 188Re) therapeutic complexes for treating the same |
| 01/22/2008 | US7321002 Chiral integrin modulators and methods of use thereof |
| 01/22/2008 | US7321001 carboxylic acid derivatives which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer |
| 01/22/2008 | US7321000 Ophthalmic composition containing N-acetyl-cysteine for the treatment of dry-eye syndrome |
| 01/22/2008 | US7320999 Immunosuppressants, organ transplantation, autoimmune diseases, rheumatic diseases |
| 01/22/2008 | US7320998 Carbohydrate analog inhibitors of alpha-amylase |
| 01/22/2008 | US7320997 Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
| 01/22/2008 | US7320996 Administering to a cancer patient an indole-2-one derivative containing pyrrole ring as protein kinase inhibitor together with a cyclooxygenase inhibitor to treat the cancer |
| 01/22/2008 | US7320995 Lung melanoma metastasis, rheumatoid arthritis, 1-isopropylsulfonyl-2-amino-6-(2-(2,6-difluorophenyl)-5-(phenyl)-imidazol-4-yl)-benzimidazole |
| 01/22/2008 | US7320994 {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chloro-phenyl)-methanone; anxiety, depression, psychosis, and schizophrenia and other psychotic disorders; neurodegenerative disorders, multiple sclerosis and amyotrophic lateral sclerosis |
| 01/22/2008 | US7320993 Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents |
| 01/22/2008 | US7320992 Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| 01/22/2008 | US7320991 Analogs of thalidomide as potential angiogenesis inhibitors |
| 01/22/2008 | US7320990 Hygroscopicity and high melting point, naphthalene-1,5-disulfonic acid salt of biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-quinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester, pulmonary disorder |
| 01/22/2008 | US7320989 E.g., {4-Chloro-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine; congestive heart failure, stroke, antiischemic, -arrhythmia, -arthritis, -diabetic, -inflammatory, -ulcer and hypotensive agents; urogenital, bone, respiratory, cardiovascular and nervous systems disorders |
| 01/22/2008 | US7320988 Methods of lowering lipid levels in a mammal |
| 01/22/2008 | US7320987 2,6-disubstituted 7-oxo-pyrido[2,3-d]pyrimidines; inhibition of LPS-induced Tumor Necrosis Factor- alpha production in THP1 cells |
| 01/22/2008 | US7320986 for treating cancer; 4'-(6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-1,1'-biphenyl-4-yl 1,4'-bipiperidine-1'-carboxylate for example |
| 01/22/2008 | US7320985 Adding a pyridonecarboxylic acid comprising lomefloxacin, norfloxacin, ofloxacin, enoxacin, ciprofloxacin, tosufloxacin, fleroxacin and/or levofloxacin; cinoxacin, sparfloxacin or salt; low temperature; antiinflammatory agents |
| 01/22/2008 | US7320984 Administering 4,5 alpha -epoxy-6 beta -(3,4-dihydro-2H-benzo[1,4]thiazino)-3-methoxy-17-methyl-morphinan; for urinary frequency, therapeutic or prophylactic effect and of which side effects are improved |
| 01/22/2008 | US7320983 Sulfur compounds such as phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate, used for prevention of viral diseases and replication |
| 01/22/2008 | US7320982 Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 |
| 01/22/2008 | US7320981 Variolin derivatives as anti-cancer agents |
| 01/22/2008 | US7320980 Substituted pyrido(1,2-a)pyrimidines and their use as NOS inhibitors |
| 01/22/2008 | US7320979 Diseases which respond to influencing by dopamine D3 receptor antagonists or agonists, diseases of the central nervous system and disturbances of kidney function; N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide |
| 01/22/2008 | US7320978 Inflammations of the respiratory system, locomotor system traumas, and edemas; 1-{[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1,3-oxazol-2-yl]carbonyl}-4-(3-methylphenyl)piperazine |
| 01/22/2008 | US7320977 Substituted 2-phenyl-3(2h)-pyridazinones |
| 01/22/2008 | US7320976 Combination of brimonidine and timolol for topical ophthalmic use |
| 01/22/2008 | US7320974 Cytoskeletal active compounds, compositions and use |
| 01/22/2008 | US7320973 5,11-Dihydrodiaryl[b,e][1,4,]oxazepine derivatives for gastrointestinal disorder treatment; irritable bowel syndrome |
| 01/22/2008 | US7320972 Hypercholesterolemia, cholesterol-associated benign and malignant tumors; hyperlipidemia, arteriosclerosis, and sitosterolemia; 6) (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(2',3',4'-trimethoxybiphenyl-4-yl)azetidin-2-one |
| 01/22/2008 | US7320971 Cardenolide glycosides, which have a cytotoxic activity, cancer |
| 01/22/2008 | US7320970 Low dose estrogen interrupted hormone replacement therapy |
| 01/22/2008 | US7320969 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 01/22/2008 | US7320968 Pharmaceutical composition |
| 01/22/2008 | US7320967 Alopecia therapy using tetrazole compound |
| 01/22/2008 | US7320965 Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease |
| 01/22/2008 | US7320964 Modulation of expression of STAT-1 dependent genes |
| 01/22/2008 | US7320963 Methods and compositions for delivery of pharmaceutical agents |
| 01/22/2008 | US7320962 Hemoactive compositions and methods for their manufacture and use |
| 01/22/2008 | US7320961 UDP-glucuronosyltransferases (UGTs), UGT1A1 being a bilirubin-specific isozyme; inducing UGT1A1 isoform expression for treating unconjugated hyperbilirubinemia by administering ritonavir; side effect reduction of AIDS drugs such as indinavir, atazanavir, amphotericin B/cholesteryl sulfate complex |
| 01/22/2008 | US7320960 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 01/22/2008 | US7320959 Transgenic aniomal nmodels; screening; administering peptide |
| 01/22/2008 | US7320875 Screening for neutralizing hepatitis C virus antibodies in a blood sample utilizing an HCV E2 protein and a protein from a human or chimpanzee cell that has a molecular weight of 24 kd that binds to the E2 protein of HCV; comparing the amount of bound proteins to that in the absence of HCV antibodies |
| 01/22/2008 | US7320805 CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| 01/22/2008 | US7320803 Free from water of crystallization; use in foods, animal feeds, or in food supplements |
| 01/22/2008 | US7320802 Improved pharmacokinetic profiles; bioadhesives |
| 01/22/2008 | US7320800 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 01/22/2008 | US7320679 Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia |
| 01/22/2008 | CA2563381C Use of purified sdg as an antioxidant |
| 01/22/2008 | CA2495967C New synthesis process and new crystalline form for agomelatine, and pharmaceutical compositions containing it |
| 01/22/2008 | CA2490638C Combination therapy wherein a serotonin reuptake inhibitor is used |
| 01/22/2008 | CA2468036C A method of treating bacterial infections using gemifloxacin or a salt thereof and a .beta.-lactam antibiotic |
| 01/22/2008 | CA2432884C Nutritional composition with health promoting action containing oligosaccharides |
| 01/22/2008 | CA2431515C Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof |
| 01/22/2008 | CA2420999C 2-substituted heterocyclic compounds and their use in treating multidrug resistance |
| 01/22/2008 | CA2404120C Use of bradycardiac agents in the treatment of myocardial diseases accompanied by hypertrophy and new drug combinations |
| 01/22/2008 | CA2392168C Vitamin d analogues |
| 01/22/2008 | CA2382577C Injectable buprenorphine microparticle compositions and their use |
| 01/22/2008 | CA2374362C Urea derivatives as hiv aspartyl protease inhibitors |
| 01/22/2008 | CA2374247C Heterocyclic derivatives useful as anticancer agents |
| 01/22/2008 | CA2347976C Plastics container containing stabilised drug formulations |
| 01/22/2008 | CA2338728C Pharmaceutical composition for injection based on paracetamol |
| 01/22/2008 | CA2333322C Nitric oxide synthase inhibitors |
| 01/22/2008 | CA2322967C Prophylactic, therapeutic agent for osteoporosis |
| 01/22/2008 | CA2316485C Sustained-release pharmaceutical composition |
| 01/22/2008 | CA2311308C Method for producing solid dosing forms |
| 01/22/2008 | CA2309629C Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
| 01/22/2008 | CA2305807C Substituted fused heterocyclic compounds |
| 01/22/2008 | CA2303807C Bioresorbable compositions for implantable prostheses |